论文部分内容阅读
目的 通过检测术前化疗与单一手术组织标本之间多种癌基因与抑癌基因分子变异的差异 ,以期探讨术前化疗对 期 NSCL C患者基因变异的影响及其临床意义。方法 分别采用 DNA印迹法及 PCR技术 ,检测 75例 期NSCL C组织 DNA标本中 c- m yc、c- erb B2及 EGFR多种癌基因扩增及 71例组织中抑癌基因 p15的纯合性丢失。结果 1)术前化疗组的多种癌基因共扩增率为 35 .5 % ,而相应单一手术组为 6 3.6 % (P<0 .0 5 )。 2 ) p15的纯合性丢失率在术前化疗组为 2 3.3% ,较单一手术组的 70 .7%有显著性降低 (P<0 .0 0 1)。结论 术前化疗对 期 NSCL C患者癌细胞具有攻击及杀伤作用 ,从而不仅使癌基因的共扩增率下降 ,而且也使抑癌基因的丢失率降低。因此检测基因的变化在一定程度上有可能作为术前化疗对于 期肺癌治疗有效性的实验室预测指标
Objective To investigate the effect of preoperative chemotherapy on gene mutation in patients with NSCL C and its clinical significance by detecting the differences in the molecular variations of multiple oncogenes and tumor suppressor genes between preoperative chemotherapy and single surgical tissue specimens. Methods Southern blotting and PCR were used to detect the polymorphisms of c-m yc, c-erb B2 and EGFR in 75 NSCLC specimens and the homozygosity of tumor suppressor gene p15 in 71 tissues Lost Results 1) Preoperative chemotherapy group a variety of oncogene amplification rate was 35.5%, while the corresponding single surgery group was 3.6% (P <0. 05). 2) The loss of homozygosity of p15 was 23.3% in the preoperative chemotherapy group, which was significantly lower than 70.7% in the single operation group (P <0.01). Conclusion Preoperative chemotherapy can attack and kill cancer cells in patients with stage NSCL C, which not only reduces the co-amplification rate of oncogenes but also decreases the loss rate of tumor suppressor genes. Therefore, the detection of gene changes to a certain extent, may be used as a preoperative chemotherapy for the treatment of lung cancer, the effectiveness of laboratory predictors